---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-343407"
form_type: "8-K"
ticker: "UPB"
cik: "0002022626"
company_name: "Upstream Bio, Inc."
filed_at: "2026-08-11T11:05:23+00:00"
generated_at: "2026-08-11T11:10:43.897108+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Upstream Bio Q2 net loss $39.7M; cash $261.3M funds through 2027; Phase 3 on track

## Summary
- Net loss of $39.7M for Q2 2026 vs $40.0M year ago; R&D spend $36.1M, G&A $7.1M.
- Cash and equivalents of $261.3M as of June 30, 2026, expected to fund operations through 2027.
- Phase 3 trials in severe asthma and CRSwNP on track to initiate Q1 2027; FDA End-of-Phase 2 meetings on schedule.
- Completed enrollment in Phase 2 VENTURE COPD trial (481 participants); data expected H2 2027.
- Phase 2 data: ~80% of verekitug-treated CRSwNP patients achieved NPS improvement; ERS late-breaking data Sept 5-9.

## SEC filing metadata
- accession: 0001193125-26-343407
- form_type: 8-K
- ticker: UPB
- cik: 0002022626
- company_name: Upstream Bio, Inc.
- filed_at: 2026-08-11T11:05:23+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022626/000119312526343407/0001193125-26-343407-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022626/000119312526343407/upb-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-343407
- JSON: https://secwatch.observer/filing/0001193125-26-343407.json
- Plain text: https://secwatch.observer/filing/0001193125-26-343407.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.